CCG Wealth Management LLC Has $282,000 Holdings in Pfizer Inc. $PFE

CCG Wealth Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 47.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,643 shares of the biopharmaceutical company’s stock after acquiring an additional 3,737 shares during the quarter. CCG Wealth Management LLC’s holdings in Pfizer were worth $282,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at about $28,000. Horizon Financial Services LLC acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.7%

Pfizer stock opened at $24.81 on Friday. The company’s 50 day simple moving average is $24.86 and its 200 day simple moving average is $24.13. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.82. The firm has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.81 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm earned $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.